Data from Phase III study of Masican (masitinib) in Pancreatic Cancer published-AB Science
AB Science has announced the publication of results from the first randomized Phase III study of Masican (masitinib) in treatment of advanced pancreatic ductal adenocarcinoma (PDAC). Findings revealed that the markers of acyl-CoA oxidase-1 (ACOX1) expression in blood and baseline pain intensity may have prognostic value, with patients from these subgroups experiencing aggressive disease progression while receiving Gemzar (gemcitabine, from Eli Lilly and Company).
In patients with over-expression of ACOX1 in blood, administration of masitinib in combination with Gemzar produced a statistically significant overall survival advantage of +6.1 months when compared with placebo administered in combination with Gemzar. In the pain subgroup, administration of masitinib in combination with Gemzar produced a statistically significant overall survival advantage of +2.6 months when compared with placebo administered in combination with Gemzar.
Safety of the combination remained acceptable with no overall detrimental effect on quality of life. A new confirmatory Phase III trial of masitinib in advanced pancreatic cancer has been initiated, with an objective to replicate these promising results in a prospective manner.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins